Top

Published in:

Open Access 01-12-2012 | Research

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

Authors: Diane Tseng, Leelanand P Rachakonda, Zheng Su, Ranjana Advani, Sandra Horning, Richard T Hoppe, Andrew Quon, Edward E Graves, Billy W Loo Jr, Phuoc T Tran

Published in: Radiation Oncology | Issue 1/2012

Abstract

Purpose

We hypothesized that quantitative PET parameters may have predictive value beyond that of traditional clinical factors such as the International Prognostic Score (IPS) among Hodgkin's disease (HD) patients.

Methods

Thirty HD patients treated at presentation or relapse had staging and interim-treatment PET-CT scans. The majority of patients (53%) had stage III-IV disease and 67% had IPS ≥ 2. Interim-treatment scans were performed at a median of 55 days from the staging PET-CT. Chemotherapy regimens used: Stanford V (67%), ABVD (17%), VAMP (10%), or BEACOPP (7%). Hypermetabolic tumor regions were segmented semiautomatically and the metabolic tumor volume (MTV), mean standardized uptake value (SUVmean), maximum SUV (SUVmax) and integrated SUV (iSUV) were recorded. We analyzed whether IPS, absolute value PET parameters or the calculated ratio of interim- to pre-treatment PET parameters were associated with progression free survival (PFS) or overall survival (OS).

Results

Median follow-up of the study group was 50 months. Six of the 30 patients progressed clinically. Absolute value PET parameters from pre-treatment scans were not significant. Absolute value SUVmax from interim-treatment scans was associated with OS as determined by univariate analysis (p < 0.01). All four calculated PET parameters (interim/pre-treatment values) were associated with OS: MTV_int/pre (p < 0.01), SUVmean_int/pre (p < 0.05), SUVmax_int/pre (p = 0.01), and iSUV_int/pre (p < 0.01). Absolute value SUVmax from interim-treatment scans was associated with PFS (p = 0.01). Three calculated PET parameters (int/pre-treatment values) were associated with PFS: MTV_int/pre (p = 0.01), SUVmax_int/pre (p = 0.02) and iSUV_int/pre (p = 0.01). IPS was associated with PFS (p < 0.05) and OS (p < 0.01).

Conclusions

Calculated PET metrics may provide predictive information beyond that of traditional clinical factors and may identify patients at high risk of treatment failure early for treatment intensification.

Available only for authorised users

Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327: 1478-1484. 10.1056/NEJM199211193272102CrossRefPubMed

Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91: 475-481.PubMed

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107: 52-59. 10.1182/blood-2005-06-2252CrossRefPubMed

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25: 3746-3752. 10.1200/JCO.2007.11.6525CrossRefPubMed

GNU Project, The Comprhensive R Archive Network. R 2.5.1Institute for Statistics and Mathematics of the WU Wien; [http://cran.r-project.org/]

Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94: 429-433.PubMed

Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P: Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999, 20: 13-20. 10.1097/00006231-199901000-00004CrossRefPubMed

Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK: Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998, 25: 721-728. 10.1007/s002590050275CrossRefPubMed

Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000, 27: 1564-1578. 10.1007/s002590000340CrossRefPubMed

10.

O'Doherty MJ, Macdonald EA, Barrington SF, Mikhaeel NG, Schey S: Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 2002, 14: 415-426. 10.1053/clon.2002.0118CrossRef

11.

Schiepers C, Filmont JE, Czernin J: PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003,30(Suppl 1):S82-88.CrossRefPubMed

12.

Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, Kühnel G, Kropp J, Hänel M, Laniado M, Kotzerke J, Ehninger G: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004, 90: 620-625. 10.1038/sj.bjc.6601561PubMedCentralCrossRefPubMed

13.

Cheson BD: The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007, 21: 841-54. 10.1016/j.hoc.2007.06.011CrossRefPubMed

14.

Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ: Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007, 25: 3902-3907. 10.1200/JCO.2007.11.9867CrossRefPubMed

15.

Grow AQE, Loo BW Jr: Metabolic tumor volume as an independent prognostic factor in lymphoma [Abstract 6594]. Journal of Clinical Oncology 2005, 23: 583S.

16.

Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20: 630-637. 10.1200/JCO.20.3.630CrossRefPubMed

17.

Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002, 20: 3081-3087. 10.1200/JCO.2002.12.101CrossRefPubMed

18.

Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M: BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998,9(Suppl 5):S67-71.CrossRefPubMed

19.

Lee PWD, Lavori P, Quon A, Hara W, Maxim P, Le QT, Wakelee H, Donington J, Graves E, Loo BW: Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiation Oncology Biol Phys 2007, 69: 328-333. 10.1016/j.ijrobp.2007.04.036CrossRef

20.

GraphPad: Kaplan-Meier Analysis. In GraphPad Prism version 4.0a for Macintosh ed. San Diego, California; 2003.

21.

Advani RH, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, Horning SJ: Stage I-IIA Non-bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. Int J Radiat Oncol Biol Phys 2010.

Title: Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
Authors: Diane Tseng
Leelanand P Rachakonda
Zheng Su
Ranjana Advani
Sandra Horning
Richard T Hoppe
Andrew Quon
Edward E Graves
Billy W Loo Jr
Phuoc T Tran
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-7-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy

Accelerated large volume irradiation with dynamic Jaw/Dynamic Couch Helical Tomotherapy

Radiosensitization by the novel DNA intercalating agent vosaroxin

Seminal vesicle interfraction displacement and margins in image guided radiotherapy for prostate cancer

Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients?

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment